Publications by authors named "Maria Psyllaki"

Claim this Profile
A
Aggressive recurrence of Non-Hodgkin's Lymphoma after successful clearance of hepatitis C virus with direct acting antivirals.
Dimitrios N Samonakis, Maria Psyllaki, Konstantia I Pavlaki, Elias Drakos, Elias Kehagias

Ann Hepatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an immunocompetent patient. A case study.
Petros Ioannou, Evangelia Akoumianaki, Konstantinos Alexakis, Athanasia Proklou, Maria Psyllaki

Germs· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production.
Maria Velegraki, Evaggelia Papakonstanti, Irene Mavroudi, Maria Psyllaki, Christos Tsatsanis

Haematologica· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
Irene Mavroudi, Katerina Pyrovolaki, Konstantia Pavlaki, Androniki Kozana, Maria Psyllaki

Leuk Res· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes.
Mirjam Klaus, Emily Stavroulaki, Maria-Christina Kastrinaki, Persefoni Fragioudaki, Krinio Giannikou, Maria Psyllaki

Stem Cells Dev· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Maria Ximeri, Athanasios Galanopoulos, Mirjam Klaus, Agapi Parcharidou, Krinio Giannikou, Maria Psyllaki

Haematologica· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired megakaryopoiesis in patients with chronic idiopathic neutropenia is associated with increased transforming growth factor beta1 production in the bone marrow.
Maria Psyllaki, Athina Damianaki, Claudia Gemetzi, Katerina Pyrovolaki, George D Eliopoulos

Br J Haematol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes.
Anna Boula, Michael Voulgarelis, Stavroula Giannouli, George Katrinakis, Maria Psyllaki

Clin Cancer Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurofibromatosis type I and smoldering multiple myeloma: a case report.
Vassiliki Danilatou, Demetra Liapi, Maria Psyllaki, Aria Chatzivasili, Irini Chronaki

Hematology· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
Helen A Papadaki, Christos Tsatsanis, Anna Christoforidou, Niki Malliaraki, Maria Psyllaki

J Bone Miner Metab· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis